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The test for antineutrophil cytoplasmic antibodies (ANCA) was 
introduced into the author's laboratory in 1987. An improved indirect 
immunofluorescent method was developed, using a system which 
allows 16 instead of one serum sample to be screened on each 
microscope slide. 
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The known disease associations of ANCA that have been explored 
include systemic vasculitis, renal limited vasculitis, chronic 
inflammatory bowel disease and HIV disease. In general the findings 
are similar to those which are emerging from other centres and 
confirm the value not only of the positivity but also the relevance of 
the intracellular disposition of the neutrophil cytoplasmic fluorescence 
in diagnosis. 
In this study 85% of patients with Wegener's granulomatosis were 
found to have C-ANCA. C, P and X-ANCA staining patterns were 
found in 57% of patients with ulcerative colitis. Forty one per cent of 
patients with symptomatic HIV have ANCA. 
Certain histological features such as neutrophil and vascular damage 
in invasive amoebiasis, and the established lytic effect of amoebae on 
neutrophils prompted the investigation of the possibility that ANCA 
may be generated in this disease. Seventy eight amoebiasis sera were 
screened and 98,70/0 gave a positive ANCA test with a pattern of 
fluorescence resembling that found in Wegener's granulomatosis. An 
ELISA test for specificity confirmed that, as in Wegener's 
granulomatosis, this amoebiasis-associated ANCA had proteinase 3 
specificity. Of practical clinical importance is the fact that both HIV 
and amoebiasis are associated with a high level of ANCA positivity. 
These findings will need to be considered when ANCA tests are used 
in clinical decision making in an area where HIV disease and 
amoebiasis are endemic. 
A large number of normal volunteer blood donors have been tested 
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INTRODUCTION 
Friedrich Wegener first described the pathology of a granulomatous 
vasculitic disease in 1936. The following exerpt is from the last 
manuscript of the pioneer work that he presented at a symposium to honor 
his 83rd birthday. The symposium on Wegener's granulomatosis (WG) and 
related vasculitic syndromes was held in Zweibrucken in 1990 and the 
manuscript was translated by H. Lehman and N Rasmussen (Lehmann 
1990). 
In 19361 (Friedrich Wegener) gave the first brief report, based on three 
post mortem examinations performed by myself, of a "new" and peculiar 
disease, which had not been recognized before. In 1939 I described this 
disease in detail and called it "rhinogenic granulomatosis". This paper is 
now considered a "classic". Since the fifties this "novel" disease is, in its 
generalized stage, clinically and anatomically characterized by a so 
called triad: 
1. A granulomatous-necrotizing and ulcerative inflammatory process of 
the respiratory tract and internal organs. 
2. A necrotizing-granulomatous general vasculitis. 
3. A usually focal, necrotizing glomerulonephritis. 
Shortly after this presentation Dr Friedrich Wegener died with the 
knowledge of the discovery of an antibody associated with the disease he 
described 50 years earlier and that had been given his name. 
Wegener's granulomatosis is often a diagnostic problem and until 10 years 
ago no specific laboratory test was available to assist in its diagnosis. In 
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1982, using an indirect immunofluorescent test Davies and co-workers 
reported autoantibodies directed against neutrophil cytoplasmic 
components in patients with necrotizing glomerulonephritis (Davies 1982). 
The impact of this observation became apparent only in 1985 when Van 
der Woude and colleagues noted that this autoantibody was present in 93% 
of patients they tested with a diagnosis of Wegener IS granulomatosis. The 
initial report by Vander W oude was soon followed by extensive 
confirmatory studies by other workers (Gross 1986, Ludemann 1987, 
Parleviet 1988). This new antibody was named ANCA, antineutrophil 
cytoplasmic antibody. In 1988 Falk demonstrated a different 
immunofluorescent ANCA staining pattern that was later to be called P-
ANCA. The association of this perinuclear staining antibody was with 
patients with necrotizing glomerulonephritis and microscopic polyarteritis 
(Jennette 199t Geffriaud-Ricouard 1993). P-ANCA has also been 
reported in 5% to 50% of patients with Churg Strauss syndrome (CSS) and 
in about 5% of patients with WG (Hoffinan 1992). A year later yet 
another ANCA variation was described, this time in patients with 
inflammatory bowel disease, and this antibody was called X-ANCA 
(Targan 1989). ANCAls have proved to be of great value in the diagnosis 
and management of patients within the large spectrum of systemic 
vasculitis (Specks 1989 (1), Cohen-Tervaert 1990 (2), Savage 1990, 
Pettersson 1992). 
The indirect immunofluorescence assay (lIP) was the first method used to 
detect ANCA and although there are many new techniques for antibody 
identification such as enzyme linked immunosorbent assay (ELISA), 
radioimmunoassay (RIA) and immunoblotting, the IIF method remains the 
accepted international gold standard. Five international workshops have 
been held since 1988 and consensus attained on both the categorisation and 
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the nomenclature of the various ANCA's. Using IIF on alcohol-fixed 
human neutrophils three different staining patterns can be identified: i the 
granular cytoplasmic pattern (C-ANCA) seen in Wegener's granulomatosis; 
ii the perinuclear pattern (P-ANCA) which is associated with necrotizing 
and crescentic glomerulonephritis and microscopic polyarteritis (mP AN) 
(Falk 1988). iii The third and unusual immunofluorescent staining pattern is 
a mixture of C and P-ANCA exhibiting a "snow storm" pattern and is 
called X-ANCA. The clinical association of this antibody is with a 
subgroup of patients with chronic inflammatory bowel disease and chronic 
active hepatitis (Targan 1989, Rump 1990, Cohen Tervaert 1992). 
The target antigens for many of these ANCA's have been identified. The 
C-ANCA antigen is predominantly proteinase 3 (PR3), a serine protease 
found in the primary granules of the neutrophil (Goldschmeding 1989(1), 
Niles 1989). Recent molecular studies have indicated that several epitopes 
within the PR3 molecule are recognised and these differences may 
correlate with varied disease expression (Lockwood 1993). The major P-
ANCA target specificity is myeloperoxidase (MFO), also a primary 
granule constituent, but other proteins such as human leucocyte elastase 
(HLE), lactoferrin (Lf), lysozyme (Lz) and cathepsin G (CG) have been 
implicated. X-ANCA associated antigens are as yet unknown. 
Different immunoglobulin isotypes have been reported in the ANCA 
associated diseases. The majority of ANCA1s in WG and mP AN are of the 
IgG isotype (Van der Woude 1989) however Jayne in 1989 reported three 
patients with pulmonary renal syndrome whose initial sera had IgM ANCA 
activity alone. All three of these patients later switched from IgM to IgG 
in keeping with the normal immune response. Patients who have 
similtaneous IgG and IgM have a marked predeliction for pulmonary 
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haemorrhage (Esnault 1993). Adult Henoch-Schonlein purpura has been 
associated with the presence oflgA ANeA (Shaw 1992, Saulsbury 1991). 
Both the ANeA isotype and the antibody specificity seem to be important 
determinants of disease expression. 
There has been speculation but no definitive proof as yet of the 
pathogenetic role of ANeA. The fact that disease recrudescence and 
remission go hand in hand with the presence and absence respectively of 
ANeA lends support to the fact that this autoantibody in the setting of 
systemic vasculitis is not an epiphenomenon (Van der Woude 1985, Van 
der Woude 1989, Kallenberg 1991, Hagen 1992). The pathogenesis of 
WG remains unclear but respiratory infection where large amounts of 
de granulating neutrophils are found, is thought to precipitate disease 
activity. ''In vitro" studies have suggested different theories for the roll of 
ANeA in the pathogenesis and the histological findings in the systemic 
vasculitides. One theory is that cytokine,tumour necrosis factor-a 
(TNF -a) activated neutrophils causes translocation of proteases to the cell 
membrane, thus making them accessible to ANeA. The ANeA-neutrophil 
binding results in a neutrophil respiratory burst and degranulation, causing 
direct damage to the cytokine activated endothelial cells. Another 
suggestion is that endothelial cells express proteases on their membranes 
that lead to direct binding of ANeA with concommitant destruction of the 
blood vessel (Gross 1993(2)). 
The introduction of the ANeA test in the Department of Medicine at the 
University of Natal medical school was stimulated by the advent of a 
severe multi-system disease in a colleague in 1987. The key publication by 
Vander W oude had appeared in the Lancet and a simplified version of the 
ANeA test was performed on this patient using a peripheral blood film as 
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substrate. The strong neutrophil cytoplasmic fluorescence facilitated a 
diagnosis and therapy was started which resulted in a lasting remission. 
Interest in and usage of ANCA increased dramatically and samples in 
excess of 2000 have been processed in the author's laboratory. With such 
a new test the opportunity arose to join the exploration into disease 
associations of AN CA in the large teaching hospital, King Edward VITI, 
and the surrounding medical environment of Durban. 
It soon became clear that the technique of the test should be modified and 
streamlined to overcome the cumbersome process of utilising one 
microscope slide loaded with substrate for each test and control sample. 
This led to the successful introduction of the 16 well chamber slide 
technique which has greatly simplified the screening process. 
CHAPTER 1 
THE INDIRECT IMMUNOFLUORSCENT ASSAY FOR THE 




THE INDIRECT IMMUNOFLUORESCENT (IlF) TECHNIQUE 
The coupling of fluorescent dyes like fluorescein to antibodies does not destroy 
their specificity. These antibody conjugates then combine with their 
corresponding antigens and can be visualised with a fluorescence microscope. 
In the indirect immunofluorescent test, a double layer technique, the 
unlabelled, unknown antibody is applied to the tissue section or cell substrate, 
(Fig 1 A), and then visualised by means of a fluorochrome conjugated anti-
human globulin (Fig 1 B). 
Using this technique with ethanol fixed human neutrophils as the substrate, 
four different immunofluorescent staining pattemscan be identified fr-om 
positive test samples ; 
1.1.1 C-ANCA cytoplasmic antineutrophil cytoplasmic antibody 
1.1.2 P-ANCA perinuclear antineutrophil cytoplasmic antibody 
1.1.3 X-ANCA atypical antineutrophil cytoplasmic antibody 
1.1.4 GS-ANA granulocyte specific antinuclear antibody 




















Photomicrograph of the C-ANCA, granular cytoplasmic immunofluorescent 
staining pattern showing perinuclear emphasis, on ethanol fixed neutrophils. 
Plate 1 
A: Normal serum negative. B: C-ANCA positive serum. (Mag. x 300) 
~ perinuclear emphasis. 
Following the description of the classical granular cytoplasmic staining of 
ANCA and its association with Wegener's granulomatosis (Van der Woude 
1985) various workers investigated the specificity of this new antibody. 
Initially the auto antigen was thought to be alkaline phosphatase (Lockwood 
1987) however this was disproved by three different groups (Rasmussen 1987, 
Gross 1987, Goldschmeding 1987). 
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In 1989 a novel myeloid serine protease, Proteinase 3 (PR3) located in the 
primary azurophilic granules of the neutrophil was identified as the C-ANCA 
target antigen by two different groups (Goldschmeding 1989 (2), 
Goldsclnneding 1989 (3), Niles 1989). Confirmation by other workers 
followed shortly afterwards (Ludemann 1990, Jennette 1990, Bini 1992). This 
29 kDa multifunctional protein PR3 was sequenced and renamed, 
" Wegener's auto antigen "by Jenne (Jenne 1990). 
The strong association of C-ANCA with Wegener's granulomatosis has been 
extensively documented (Van der Woude 1985, Cohen-Tervaert 1989, Gross 
1986, Harrison 1989, Nolle 1989, Parlevliet 1988, Specks 1989 (2) ). 
In various studies the specificity of C-ANCA for biopsy proven Wegener's 
granulomatosis was shown to be around 90%. Depending on the ·extent and 
the activity of the disease phase, the sensitivity varied from 50% in patients 
with early disease, and close to 100% in patients with active, generalised 
systemic disease. In most patients on treatment or in complete remission, 
ANCA is either absent or the antibody titre is reduced {Vander W oude 1985, 
Nolle 1989, Cohen-Tervaert 1990 (1)): However in some patients titres do not 
correlate with disease activity (Hoffman 1992, Kerr 1993). 
Although the majority of patients with C-ANCA have Wegener's 
granulomatosis the antibody has been found in small numbers of patients with 
closely related vasculitic disorders such as microscopic polyarteritis (mP AN) , 
Churg-Strauss Syndrome (CSS) and classic polyarteritis nodosa (c PAN) 
(Cohen-Tervaert 1989, Falk 1990, Bleil 1991). 
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"False positive" C-ANCA's have been reported in infections such as 
symptomatic human immunodeficiency virus (mV) infection (Koderisch 1990, 
Davenport 1991, Klaasen 1990, Klaasen 1992), in pneumonia and infections in 
cystic fibrosis (Efthimiou 1991). 
A new C-ANCA (Proteinase 3 specific) association is documented in this 
thesis in patients with invasive amoebiasis (Chapter 2.4). 
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1.1.2 P-ANCA 
Photomicrograph of the P-ANC~ perinuclear immunofluorescent staining 
pattern on ethanol fixed neutrophils. 
Plate 2 
A: Nonnal serum negative. B: P-ANCA positive serum.(Mag. x 300) 
The P-ANCA staining pattern illustrated above is the fortuitous result of a 
fixation artefact. When neutrophils are dried on slides, both the cell and 
granule membranes become penneable. During subsequent alcohol fixation, 
soluble positively-charged neutrophil granule constituents such as myelo-
peroxidase, elastase, cathepsin G and lactoferrin translocate and bind to the 
negatively charged neutrophil nucleus (FaIk 1988), (Fig 2 A). 
Fig2~B&C 





Positively charged MPO 
migrates to negatively 
charged nucleus 
INDIRECT IMMUNOFLUORESCENCE 
P- ANCA GS- ANA 
MPO Deficient Neutrophils 
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Falk in 1988 first showed that the P-ANCA staining pattern was associated 
with autoantibodies directed against myeloperoxidase (Fig 2 B). To confirm 
the specificity of MPO P-ANCA the serum sample is tested on a 
myeloperoxidase deficient neutrophil substrate. An MPO specific P-ANCA 
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will be negative on this substrate (Fig 2 C). Although most P-ANCA's are 
specific for MPO (Jennette 1990), HLE, CG, Lf, beta-glucoronidase and Lz 
have also been shown to be P-ANCA target antigens (Lesavre 1991, 
Halbwachs-Mecarelli 1992, Martensson 1992, Lesavre 1993). Further antigen 
specificities are still to be defined as some P-ANCA positive sera are non 
reactive using ELISA's and immunoblots for all the currently known P-ANCA 
target autoantigens, hence the list ofP-ANCA specificities is likely to grow. 
P-ANCA is found in many vasculitides, including segmental necrotising 
glomerulonephritis, mP AN, CSS in a small number of patients with PAN and 
WG (Jennette 1989, Chapter 2.5 page 78). P-ANCA has also been reported 
in patients with chronic inflammatory rheumatic disorders ie; rheumatoid 
arthritis, Still's and Felty's syndromes, systemic lupus erythematosus (SLE), 
mixed connective tissue disease, Sjogren's syndrome and in inflammatory 
bowel diseases (Gross 1991, Juby 1992, Savige 1991, Saxon 1990, Duerr 
1991 (I), Duerr 1991 (2)). 
Myeloperoxidase and HLE specific P-ANCA's have been detected in patients 
with infections such as post streptococcal glomerulonephritis, Legionnaires' 
disease and atypical pneumonia (Gallicchio 1991). Comely in 1993 reported 
the presence of P-ANCA by immunofluorescence in thirty eight of sixty four 
mv infected patients with symptomatic disease. Drug induced P-ANCA has 
been documented, the drugs responsible being hydralazine, clozapine and L-
tryptophan (Nassberger 1990, Almroth 1992, Jaunkalns 1992, Cilursu 1991). 
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l.l.3 X-ANCA 
Photomicrograph of the X-ANCA immunofluorescent staining pattern on 
ethanol fixed neutrophils. 
Plate 3 
A: Normal serum negative. B: X-ANCA positive serum. (Mag. x 300) 
X-ANC~ also called A-ANCA, (atypical ANCA) has the appearance of a 
combination of C and P-ANCA resulting in a "snow storm" pattern on indirect 
immunofluorescence was first documented by Rump in 1990. He called it a 
new type ofP-ANCA but X or A-ANCA has been more recently accepted as 
the nomenclature of choice (Gross 1993 (1)). When the author first 
encountered this antIbody in 1991 it was named M-ANCA, mixed ANCA, a 
mixture of C and P-ANCA. 
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The clinical associations of this antibody are subgroups of patients with 
chronic inflammatory bowel disease, primary sclerosing cholangitis and 
patients with autoimmune hepatitis (Rump 1990, Cohen-Tervaert 1992). The 
target antigen involved with this staining pattern is not yet known. 
The following photomicrographs show some unusual, atypical X-ANCA 
staining patterns encountered by the author that do not confonn to the "snow 
stonn" mixed C and P-ANCA pattern described in the literature. No doubt 
new specificities will soon emerge and new disease associations will be made. 
Plate 4 
X-ANCA ~ granule "spill" (Mag. x 800) 
X-ANeA found in a 69 year old woman who presented with Sjogren's 
syndrome. The ANA was described as homogeneous with a ground glass 
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appearance. Tests for antibodies specific for double stranded DNA (ds-DNA), 
Sjogren's syndrome associated antibody a (SSa), Sjogren's syndrome 
associated antibody b (SSb), Smith (Sm) and ribonuclear protein (RNP) were 
negative. Both nuclear and granular cytoplasmic staining is apparent with 
membrane disruption of all the neutrophils resulting in fluorescent staining 
granule "spill". 
Plate 5 
X-ANCA ~ irregular patches of intense fluorescent staining (Mag. x 800) 
X-ANeA found in a 26 year old woman with a diagnosis of SLE. Screening 
for antinuclear antibody (ANA) on a composite block tissue section and a 
human epithelial cell line (HEp-2) was negative. Ribosomal cytoplasmic 
staining was noted on the HEp-2 cell substrate. Tests for antibodies reacting 
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with ds-DNA, SSb, Sm and RNP were negative, however using an ELISA 
assay, antibodies specific for SSa were found. Definite perinuclear 
fluorescence is present as well as granular cytoplasmic staining. In many 
neutrophils irregular patches of intense fluorescent staining can be seen. 
Plate 6 
X-ANCA ~ non mriform perinuclear staining (Mag. x 800) 
X-ANeA found in a 10 year old black female (Clinical studies Case 13, 
Chapter 2.6). The differential diagnosis in this child was; hyper~eosinophilic 
syndrome or PAN with hepatitis B antiginaemia. All tests for ANA were 
negative. Areas of perinuclear fluorescent staining are evident however there 




Photomicrograph· of the granulocyte specific antinuclear antibody (GS-ANA), 
immlUlofluorescent staining pattern on ethanol fixed neutrophils. 
Plate 7 
A: Normal serum negative. B: GS-ANA positive serum.(Mag. x 800) 
In 1959 Calabresi reported on fluorescent antibody studies in leucopenic 
patients . He described this antibody as one with affinity for nucleoproteins of 
neutrophils alone. The staining patterns in the photomicrographs reproduced in 
his article 34 years ago are identical to those which are currently called GS-
ANA or P-ANCA. The serum samples were from one patient with systemic 
lupus erythematosus and one with Felty's syndrome. In 1964 this antibody was 
again reported in a patient with Felty's syndrome (Faber 1 964). Granulocyte 
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specific antinuclear antibodies were thoroughly investigated by Wiik ill 
patients with rheumatoid arthritis (Wiik 1980). 
Using alcohol fixed neutrophils the immunofluorescent staining pattern of P-
ANCA and GS-ANA look identical. Various methods are used to distinguish 
between the two. When tested onformalin fixed neutrophils, P-ANCA exhibits 
a cytoplasmic immunofluorescent staining pattern as the granule constituents 
remain in situ with this method of fixation whereas GS-ANA still shows 
nuclear fluorescence. (Cross linking fixation is thought by some workers to 
damage nuclear proteins and formalin is not recommended as a standard 
fixative for an ANCA substrate). Workers have also demonstrated that in 
patients with ulcerative colitis, autoimmune liver diseases and rheumatoid 
arthritis, (Savige 1991, Kallenberg 1992, Mulder 1993) the perinuclear pattern 
seen on ethanol-fixed neutrophils turns into a cytoplasmic pattern when 
neutrophils are fixed with paraformaldehyde. Using an MPO deficient 
neutrophil substrate a worker is able to distinguish between MPO specific P-
ANCA and GS-ANA but not between the other P-ANCA specifities such as 
Lf, HLE and CG. Myeloperoxidase specific P-ANCA will show no 
immunofluorescent staining on this substrate while the GS-ANA and the other 
P-ANCA specificities still exhibit nuclear fluorescence (Figure 2 B,C). 
The clinical association of this antibody overlaps with that ofP-ANCA and X-
ANCA and is reported in autoimmune chronic active hepatitis. (Cohen-
Tervaert 1992) There are numerous reports ofP-ANCA/GS-ANA association 
in patients with rheumatoid arthritis and Felty's syndrome (Wiik 1980, Juby 
1992, Mulder 1993). 
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The exact specificity of GS-ANA remains controversia1. Unlike ANA which is 
an organ non specific nuclear antibody (ON-ANA), GS-ANA is said to be 
specific for the nucleii of neutrophils alone (Wiik 1980). In contrast however 
since 1989, several groups have demonstrated that most if not all, GS-ANA are 
in fact recognising cytoplasmic antigens (Kallenberg 1992). 
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1.2. BUFFY COAT SMEAR NEUTROPHIL SUBSTRATE 
1.2.1 PREPARATION 
MATERIALS 
1. 10 ml of ethylene-diamine-tetra-acetic acid (EDTA) anticoagulated blood 
from a healthy group 0 positive voltmteer. 
2. Alcohol-cleaned standard glass microscope slides. 
3. Foetal Calf Serum (FCS) (Gibco) 
4. Preservative-free heparin (Pularin Glaxo) diluted in distilled water to a 
concentration of 200 iu/ml 
5. Absolute alcohol pre-cooled at -200C in a standard domestic freezer. 
METHOD 
1. Avoiding bubbles pipette ethylene-diamine-tetra-acetic acid (EDTA) 
blood into Westergren ESR tubes. 
2. Centrifuge the tubes at 1400 x g for 30 minutes. 
3. Pipette off and discard the plasma. 
4. Gently remove the buffy coat at the red cell interface with a plastic 
pasteur pipette. 
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5. Suspend the leucocytes in Iml of FCS with 20J.11 of heparin to prevent 
clumping of the white cells. 
6. Adjust the cells to a count of 45 x 106 Iml in the FCS/heparin diluent. 
7. Make thin smears on the prepared microscope slides. 
8. Air dry the slides for 2 hours at room temperature. 
9. Fix the smears for five minutes in absolute alcohol pre-cooled at -20°C 
10. Allow the slides to dry and store them in slide boxes at -200C. 
1.2.2 INDIRECT IMMUNOFLUORESCENT ASSAY 
MATERIALS 
1. Buffy coat preparations of human leucocytes on glass microscope slides. 
2. Glass coverslips. 
3. Dako marking pen. 
4. Black koki glass marking pen 
5. Phosphate buffered saline (PBS) 0,05M phosphate-O,1 NaCI pH 7,2. 
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6. Sera: test and controls; C and P-ANCA positive and nonnal serum. 
7. Fluorescein-conjugated sheep polyvalent anti-human globulin (anti-IgG, 
19A and IgM, (FITC-GAM). Wellcome MFO 1 (Murex). 
8. Fluoromount (Gurr). 
9. Moist chamber. 
10. Stainless steel container with a magnetic stirrer. 
METHOD 
1. Remove the huffy coat prepared slides from the deepfreeze and dry them 
lmder a fan for 3 minutes. 
2. Mark the test area with a Dako pen (a circle of about 1,5cm 
diameter).This fonns a "well" to prevent the serum sample from running 
across the slide. 
3. Dilute the test and control serum samples 1 in 10 in PBS (50JlI serum 
+450JlI PBS). 
4. Mix the diluted serum using a pipette and gently cover the marked area on 
the slide with approximately 200JlI of each sample. (All test and control 
samples are tested in duplicate). 
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5. Incubate the slides in a moist chamber for 30 mins at room temperature. 
6. Very gently wash off the serum from each slide with PBS delivered from 
a wash bottle with a nozzle tube, then wash the slides in PBS in a 
stainless steel container gently stirring with a magnetic stirrer. 
7. Prepare a 1 in 20 dilution of the FITe-GAM in PBS. 
8. Shake each slide to remove the excess buffer and add 200J.11 of the 
conjugate to cover the marked area on each slide. 
9. Incubate in a moist chamber for 30 minutes at room temperature. 
10. Wash the slide as in step 6. 
11. Shake off the excess buffer and mount with the mountant, (Fluoromount), 
and the appropriate sized coverslip. 
12. Outline the test area from underneath the slide with a black koki marker 
to facilitate finding the test area when examining the slides. 
13. Examine the neutrophils under a UV microscope at 200x and 400x 
magnification. 
IMPORTANT NOTE. Avoid complete drying of the slides during any step of 
the staining procedure. 
1.3 DEVELOPMENT OF A NEW INDIRECT 
IMMUNOFLUORESCENT METHOD. 
16 WELL CHAMBER SLIDE 
1.3.1 INTRODUCTION 
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The first method used to detect ANeA was the indirect immunofluorescence 
assay, originally applied for the detection of GS-ANA (Wiik 1980) and it is 
still used in the same way today. 
There have been five international workshops on ANCA to standardise the 
interpretation and the application of the various techniques used for the 
identification of these antibodies. At present the indirect immunofluorescent 
technique with alcohol fixed intact neutrophils as the substrate is the most 
widely used and is accepted as the "gold standard" (Wiik 1989, Gross 1993 
(1)). At the frrst workshop in Copenhagen in 1988 Wiik proposed a standard 
procedure for the lIF detection of these antibodies. The procedure is 
summarised below. 
Cell source Human donor peripheral blood with leucocyte preparation carried 
out immediately. 
Cell substrate Whole leucocyte population including a small proportion of 
contaminating red cells. 
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Anticoagulant Heparin with differential centrifugation to eliminate platelets, or 
defibrination. 
Sedimentation agent Methyl cellulose with hypaque. 
Washing medium Phosphate buffered saline pH 7,4 containing 1 % human 
serum albumin. Two washes. 
Leucocyte deposition on slides Cytocentrifugation or smearing techniques. 
Fixation 96-990/0 ethanol at 40 C for 5 minutes with quick drying. 
Patients serum Dilute 1 in 20 in phosphate buffered saline. 
Conjugate Rabbit IgG specific for human gamma chains diluted lin 25 to 1 in 
50 in PBS. 
Microscope Bpi-illumination with a relatively narrow band FITC primary 
interference filter. 
At the following four workshops the IIF assay was still favoured and has 




In the author's laboratory between 1987 and 1991 buffy coat leucocyte smears 
(Chapter 1.2) were used as the source of the neutrophil substrate for the 
indirect immunofluorescent assay. Unfortunately access to a cytocentrifuge 
was not possible so this had to be the method of choice. 
The buffy coat smear method had many disadvantages. It neccesitated one 
slide per test hence to test 5 patients and three controls in duplicate 16 slides 
were required. As the routine requests for this test increased it became 
unmanageable. The technical steps were difficult and the washing procedures 
long and unsatisfactory. Although the same source of blood was used for the 
substrate throughout the first four years there were qualitative differences from 
batch to batch and even differences between slides within the same batch of 
smears. 
Chamber slide culture vessels have been used extensively in tissue culture 
laboratories for in situ culture analysis. A new 16 well chamber slide was 
introduced by NUNC in 1992 designed for use with standard eight channel 
dispensers and aspirators for quick filling and replenishment of media for tissue 
cultures (plate 8). It was decided to experiment with these chamber slides as 
an alternative to thebuffy coat smears. A chamber slide 16 IIF method was 
successfully developed using pure neutrophils as the substrate. (Chapter 1.3.3). 
Many advantages of this new technique were found. 
1. Cell morphology of the attached neutrophils is well maintained and the 
various staining patterns are easily identified. 
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2. Reading of the results is expedited by having 16 tests on a single slide, 
allowing easy reference to the controls (plate 9). 
3. The technical steps are much simpler and faster. 
4. Titration of antibody activity is easily accomplished. 
5. Relatively small numbers of substrate cells are needed, 20ml of blood 
provides neutrophils for 10 chamber slides or 160 tests. 
Before introducing this method into the laboratory for use as the routine 
substrate for the lIF ANeA assay, 96 stored samples of known positive sera 
and negative cotrols were tested in parallel with the buffy coat smear substrate. 
The results with the two methods were in complete agreement. The 
morphology of the neutrophils in the chamber slides was far superior to that of 
the buffy coat, facilitating the reading and identification of the different 
fluorescent staining patterns. 
The majority of the tests carried out in this study were performed using the 16 
well chamber slide neutrophil preparations. 
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Plate 8 
16 Well Chamber Slide (A-E) 
A. Composite 16 well chamber slide 
B. Lid 
C. Detachable plastic wells 
D. Rubber sealing gasket 
E. Glass slide 
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Plate 9 




1. 20ml of venous blood was drawn from a healthy group 0 positve 
volunteer, into preservative free heparin (Pularin Glaxo) 20 iu heparin/ml 
blood. 
2. Lab Tek 16 well chamber slide 178599. 
3. Hank's balanced salt solution (HBBS) (Oxoid). 
4. Eagles minimum essential medium (MEM) (Sigma). 
5. Foetal calf serum (PCS) (Gibco). 
6. Histopaque-1119 and Histopaque-1077 (Sigma). 
7. 15ml plastic tissue culture tubes (NUNC). 
8. Repeating Eppendorf or multichannel pipette. 
9. Humidified 370 C incubator with 50/0 carbon dioxide in air. 
10. 20ml syringe with a 21 guage needle. 
11. Absolute alcohol pre-cooled at -20oC in a standard domestic freezer. 
27 
12. Storage container with a firm sealing lid (Tupperware). 
13. Dessicant. 
METHOD (Boyum 1968 (1)~ Boyum 1968 (2)) 
1. Dilute the heparinised blood 1 + 1 in HBSS. 
2. Add 3,5ml of Histopaque-1119 to each of the tissue culture tubes. (Six. 
tubes are needed for 20ml of blood). 
3. Carefully layer 3,5ml of Histopaque-l077 onto the Histopaque-l119. 
Hold all the tubes to the light to check that the gradient line is clearly 
visible. 
4. Carefully layer 6ml of the diluted heparinised blood onto the upper 
solution in the tissue culture tube. 
5. Centrifuge the tubes at 700 x g for 30 minutes at room temperature. 
6. Carefully remove the tubes from the centrifuge. One distinct layer at the 
upper 1077 interface can be seen. This is the mononuclear cell interface. 
The layer at the second, 1119 interface is indiscemable and blurred, 
contrary to the information provided on the Histopaque manufacturers 
package insert (Fig 3). Remove the cells from and into the second (1119) 




C • ERYTHROCYTES 
Double density gradient, neutrophil separation. 
NOTE. The author's experience with this technique has shown that without 
exception there has never been a clear neutrophil layer at the 1119 interface. 
Initially all the cell preparations were checked for neutrophil purity by 
smearing and staining the harvested cells, identifing and counting them under 
light microscopy. Neutrophil purity ranged from 95% to 98% in these 
preparations. 
7. Wash the harvested cells once in Eagles MEM at 350 x g for 7 minutes. 
8. Very gently resuspend the cell button in Eagles MEM with 10% FCS. 
9. Adjust the cell count to 0,5x106/ml with Eagles MEM with 10% FCS. 
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NOTE. Various concentrations of neutrophils were added to the chamber 
wells rangingfrom 2,0 x 1061ml to 0,25 x 1061ml. 0,5 x 1061ml was found to 
be the most suitable, with an even spread of cells and approximately 100 cells 
per microscope field at 200 x magnification. 
10. Add 200111 of the cell suspension to each chamber well, mixing the 
suspension regularly to ensure cell number uniformity. Cover the 
chambers with the matching chamber lid. (1,0 x 105cells Iwell). 
11. Incubate the chambers at 370 C for one hour under optimal tissue culture 
conditions i.e. humidified incubator with 5% C02 in air. 
12. After one hour examme the wells usmg an inverted phase contrast 
microscope to check the attachment of the neutrophils to the surface of 
the slide. 
13. Carefully remove the supernatant from each well with a syringe and 
a 21 guage needle. 
NOTE. Different methods for removing the supernatant were compared, (a) 
simply throwing off the supernatant, (b) sucking the supernatant off with an 
ELISA plate washer and (c) the syringe and needle method. The syringe and 
needle method was the method of choice as this caused the least disturbance 
to the neutrophil "carpef'. 
14. Invert the chamber slide and gently pat dry on a tissue. 
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15. Air dry the neutrophils for 2 hours at room temperature. 
16. Fix the neutrophils with pre-cooled lce cold absolute alcohol for 5 
minutes (200Jl1!well). 
17. As soon as the cells have dried store the chambers at -20oC in a sealed 
container with a dessicant. 
20ml of blood yields neutrophil substrate for 10 chambers, 160 tests. 
1.3.4 INDIRECT IMMUNOFLUORESCENT ASSAY. 
16 WELL CHAMBER SLIDE 
MATERIALS 
1. Pure neutrophil preparations in the multiwell chamber 16 slide. 
2. Glass coverslips 22x74mm (Lab Tek 171080). 
3. Black koki glass marking pen. 
4. PBS. 
5. Sera: test and controls; C and P-ANCA positive and nonna! serum. 
6. FITC-GAM. 
7. Fluoromount. 
8. Moist chamber. 





1. Remove the chamber slide from storage in the sealed container at -200 C. 
2. Dry the chamber slide under a fan at room temperature for 3 minutes. 
3. Dilute the test serum samples and the appropriate controls 1 in 10 in PBS 
(50}.!1 serum + 450}.!1 PBS). 
4. Mix the diluted serum with a pipette and place 200}.!1 in each well. (All 
test and control samples are tested in duplicate). 
5. Cover the chambers with the matching lid and incubate them in a moist 
chamber for 30 minutes at room temperature. 
6. Invert the chamber slide, throwing off the test samples and flick to 
remove the excess fluid. 
7. Wash the chambers with 250}.!1 of PBS/well throwing off the PBS and 
flicking the chamber between each of the five washes. 
8. Prepare a 1 in 40 dilution of the FITC-GAM in PBS. 
NOTE. In the author's laboratory the fluorescein labelled anti-human 
globulin has always been used at 1 in 20 dilution in PBS. In an attempt to 
trim expenditure in this assay a 1 in 40 dilution of the FITC-GAM was 
compared with the 1 in 20 dilution. Sixty four samples including controls 
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were tested in parallel with the two dilutions of the conjugate. No difference 
in either the presence, staining pattern or intensity of the fluorescence in the 
positive samples was noted, nor was there any difference in the background 
"glow" of the negative samples. 
9. Add 200J.11 of the FITC-GAM to each well. 
10. Cover and incubate the chamber in a moist container for 30 minutes at 
room temperature. 
11. Repeat steps 6 and 7. 
12. Mark the circles of the 16 wells on the underside of the slide with a black 
koki pen. This facilitates finding the wells when examining the slides. 
13. Remove the partitioned chambers and sealing gasket (plate 5 B andC). 
14. Pipette one drop of mountant on to each marked well of the slide and 
cover with the matching long coverslip. 
15. Examine under a UV microscope at 200x and 400x magnification. 
IMPORTANT NOTE. Avoid the complete drying of the chamber wells 
during any step of the staining procedure. 
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1.3.5 STORAGE 
The recommended storage time at -20oC of the different neutrophil substrates 
for the indirect immunofluorescent test varies from four to eight weeks. 
(Wiik1989 and Venning 1990). The multiwell chamber slides have been stored 
for as long as three months with no .deterioration in either the neutrophil 
morphology or the intensity of the fluorescent signal. 
The following photomicrographs show the C and P-ANCA fluorescent patterns 
on two substrates, stored for one month and three months, testing the same 
serum samples on the same day (Plate 10 and Plate 11). 
Plate 10 
A: C-ANCA (01/06/93) B: C-ANCA (17/08/93) (Mag. x 300) 
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Plate 11 
A: P-ANCA (01106/93) ~: P-ANCA (17/08/93) (Mag. x 300) 
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1.4 PREPARATION OF A MYELOPEROXIDASE DEFICIENT 
NEUTROPHIL SUBSTRATE 
1.4.1 INTRODUCTION 
Homozygous hereditary myeloperoxidase deficiency, probably an autosomal 
recessive disorder occurs in approximately 1 in 3000 individuals (Nauseef 
1988). 
A private pathology laboratory in Durban uses the Technikon H2 for automatic 
full blood counting using flow cytochemistry. In this system neutrophil 
peroxidase in the presence of hydrogen peroxide and an appropriate electron 
receptor chromogen, develops a darkly-coloured material which precipitates in 
the cells. With the use of electronic thresholds to separate the cell types 
passing through the flow cell, a scattergram is generated and cell differentiation 
accomplished (Fig 4). The neutrophils of a myeloperoxidase deficient 
individual will therefore not appear in the neutrophil area of the scattergrarn, 
(Fig 5), and are counted as large unstained cells (LUC). A manual differential 
count is then done on a stained blood smear and the neutrophils are easily 
identified and enumerated. 
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Fig 4 
TECHNIKON H2 SCATTERGRAM OF NORMAL NEUTROPHILS 
Fig 5 
TECHNIKON H2 SCATTERGRAM OF MYELPEROXIDASE DEFICIENT 
NEUTROPHILS 
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Throughout this study Mr T.F, a myeloperoxidase deficient, healthy young 
man kindly donated 20 mls of his blood whenever it was required. 
1.4.2 MATERIALS AND METHODS 
The myeloperoxidase deficient neutrophil substrate was prepared by the 16 
well chamber slide technique (Chapter 1.3.3 and l.3.4) and stored at -200C. 




ANCA AND DISEASE 
2.1 SYSTEMIC VASCULITIS 
2.1.1 INTRODUCTION 
The systemic vasculitides are inflammatory diseases of the blood vessels which 
may rapidly lead to end organ failure and death. They were first classified by 
Fauci in 1978. The diverse presenting features of these illnesses often lead to 
clinical and diagnostic problems and until recently the diagnosis was based on 
clinical features and tissue biopsy, the latter at times being inconclusive or 
difficult to interpret and resulting in delays. With the development of the 
ANCA test, a specific serological marker is now available that is of real value 
in establishing a diagnosis before respiratory or renal failure becomes 
irreversible. 
In 1982 Davies first documented the finding of ANCA in 8 patients with 
segmental necrotizing glomerulonephritis (Davies 1982). Vander Woude 
initially reported the presence of this antibody in twenty five of twenty seven 
(93%) patients he tested with active Wegener's Granulomatosis, and more 
recently Kerr reported C-ANCA in forty four of fifty (880/0) patients with W.G. 
(Van der Woude 1985, Kerr 1993). 
In 1988, Falk and Jennette reported two distinct immunostaining patterns of 
ANCA when using ethanol fixed neutrophils; C-ANCA, the classical granular 
cytoplasmic staining pattern primarily associated with Wegener's 
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Granulomatosis and microscopic polyarteritis; and P-ANCA, the perinuclear 
staining pattern associated with the renal limited vasculitides (Falk 1988). 
2.1.2 STUDY POPULATION 
F our hundred and eleven blood samples from patients suspected of having 
systemic or renal limited vasculitis were received in the laboratory for routine 
ANCA testing over a period of four years (1988-1992). Two hundred and 
thirty four were from Black, ninety five from Indian and eighty two from White 
patients (Fig 6). 
Fig 6 
STUDY POPULATION (411 PATIENTS) 
2.1.3 METHODS 
Patients' serum samples were divided into two tubes and stored at -20oC until 
assayed. Samples were thawed once for testing, re-freezing and thawing of 
sera was avoided. 
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The samples received from 1988 to June 1992 when the new method was 
developed were tested for ANCA using an indirect immunofluorecent assay 
with buffy coat smears as the source of the neutrophil substrate (Chapter 
1.2.2). The remainder were tested by indirect immunofluorescence using the 
chamber 16 slide method~ (Chapter 1.3.4). All samples were tested in 
duplicate. From 1990 onwards all samples that were found to be P-ANCA 
positive on the standard normal neutrophil substrate were tested for ANCA on 
a myeloperoxidase deficient substrate. 
The patients having a positive ANCA test were classified by defined criteria 
laid down by Fauci in 1978. 
Wegener's Granulomatosis (WG) : destruction of upper and/or lower 
respiratory tract with glomerulonephritis in most cases. This diagnosis was 
accepted if the biopsy revealed a small vessel vasculitis or a 
necrotizing/crescentic glomerulonephritis. 
Syndrome of Systemic Vasculitis : a non-specific clinical syndrome with at 
least two of the following features : anorexia~ anaemia, arthralgia, fever, 
malaise, myalgia and weight loss in the absence of infections, malignancy or 
metabolic abnormalities. 
Classical Polyarteritis nodosa : illness with features of systemic vasculitis and 
damage to at least two major organs. Confirmation of the diagnosis was 
dependent on the biopsy showing vasculitis of medium sized vessels without 
granuloma formation. The final diagnosis was obtained using these criteria 
after reviewing the hospital charts. 
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2.1.4 RESULTS 
Fifty eight (14%) of the 411 patients suspected of having systemic vasculitis 
tested positive for ANCA. The "group consisted of 35 males and 23 females, 
with an age range from 12 to 72 years and a mean age of 44. 
Of the total, 234 were from Black patients of which 21 were positive, 82 from 
White patients with 21 positive and 95 from fudian patients, 16 of whom were 
positive (Fig 7). 
Fig 7 
DEMOGRAPIDC DATA OF ANCA POSITIVE PATIENTS 
\ ANCA POSITIVB : 14 ~ (58 of 411) 
DEMOGRAPHIC DATA : 
AGE : fUle= 11·72 yean 
mean= 44 ,ears 
SEX"' : MALES- 35 
FEMALES= 23 
RACE: wmm 251J> 
(21 out of 82 samples) 
INDIAN 171J> 
(16 out of 95 II8DIplea) 
BLACK 9~ 
(21 out of 234 II8DIples) 
80 • 
43 
Two patterns of ANCA positivity were identified in these 58 patients, 33 
having C-ANCA and 25 P-ANCA as shown in Fig 8. 
Fig 8 
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Wegener's granulomatosis was diagnosed in 23 (70%), the majority of the 
patients with C-ANCA. The P-ANCA associations were much more diverse 
with a diagnosis of Wegener's inA (16%) and systemic vasculitis in 10 (40%) 
of these patients (Fig 9 and Fig 10). 
Fig 9 
DISTRIBUTION OF DISEASE IN C-ANCA POSITIVE PATIENTS 
WEGENER'8 GRANULOM. 
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A further breakdown of the 10 patients with P-ANCA and systemic vasculitis 
is shown in Fig 11. 
Fig 11 
P-ANCA IN 10 PATIENTS WITH SYSTEMIC VASCULITIS 
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The organ involvment data (Fig 12) and the representative case reports 
(Chapter 2.6) illustrate the diversity of the presenting symptoms, with renal and 
pulmonary features predominating, as described in previous reports. 
Fig 12 
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The clinical presentation of these patients ranged from limited renal disease to 
varying degrees of systemic involvment (Chapter 2.6). This resulted in 
patients presenting to ear nose and throat surgeons, pulmonologists, 
rheumatologists, opthalmologists and general physicians. Requests for the 
ANCA test were often delayed. Many of the ANCA associated diseases are 
rapidly progressive, leading to irreversible organ damage and early immuno-
suppressive therapy is of great importance. 
The sex distribution of ANCA positive patients in this study showed a male 
predominance in keeping with the findings reported in other studies (Adu 
1987). ANCA was found more often in White patients, (25% of samples 
tested) than in Black patients, (9%" of samples tested). This is in agreement 
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with the report of F a1k in 1991, and could be attributed to the higher incidence 
of Wegener's granulomatosis amongst the White subjects. 
C-ANCA has a reported specificity of almost 900/0 for Wegener's 
granulomatosis and microscopic polyarteritis, (Nolle 1989, Specks 1989 (1)) 
and in our study C-ANCA was identified in 85% of all cases ofWG. P-ANCA 
is found in patients with a wider range of disorders and has been extensively 
associated with necrotizing and crescentic glomerulonephritis (Wathen 1987, 
Jemlette 1989). Our patients with P-ANCA also fell into this category. (Fig 10 
and Fig 11). 
It is well recognised that some biopsies may be hazardous and technically 
difficult in these patients and that the histology is often inconclusive (D'Cruz 
1989, Case 1, Chapter 2.6). The finding of ANCA in these patients is 
extremely useful in making a definitive diagnosis enabling prompt treatment 
to be started. Although there is contradictory evidence in the literature the 
serial monitoring of ANCA in these patients helps in their clinical assessment 
while on treatment and also helps in the differentiation of infection and relapse 
( Specks 1989 (2), Egner 1990, Pettersson 1992, Kerr 1993). 
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2.2 INFLAMMATORY BOWEL DISEASE 
2.2.1 INTRODUCTION 
At the third international workshop on ANCA in Washington DC in 1990 three 
different working groups reported the presence of ANCA in patients with 
inflammatory bowel disease. They found that the prevalence of the 
antineutrophilcytoplasmic antibody in ulcerative colitis was 530/0, 64% and 
230/0 respectively and the predominant staining pattern was P-ANCA 
(Cambridge 199t Rump 1991, J0rgensen 1991). In patients with Crohn's 
disease the antibody frequency reported was much lower at 100/0, 11 % and 
11 % and the staining pattern was also P-ANCA. These P-ANCA's were not 
myeloperoxidase specific and other target antigens such as lactoferrin were 
suggested. 
Using an intact neutrophil enzyme linked immunsorbent assay (ELISA) Saxon 
and co-workers undertook a blind study and found that twenty one of twenty 
five patients with ulcerative colitis and five of twenty five patients with Crohn's 
disease had antibodies to neutrophil cytoplasmic components (Saxon 1990). 
Duerr in 1991 confirmed a high prevalence of ANCA of 850/0 in ulcerative 
colitis and a prevalence of 780/0 in patients with ulcerative colitis who had 
undergone colectomy. Duerr also used a fixed neutrophil ELISA, and ELISA 
assays for specific antigens such as MPO, HLE and CG (Duerr 1991). He 
concluded that these ulcerative colitis associated ANCA's were not directed 
against any of the known cytoplasmic antigens. In 1992 Halbwachs-Mecarelli 
and co-workers found that in their study there was a strong association 
between ulcerative colitis, primary sclerosing cholangitis and ANCA specific 
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for CG (Halbwachs-Mecarelli 1992). In a recent study by Oudkerk Pool, P-
ANCA was reported in 790/0 of patients with ulcerative colitis, in 130/0 of 
patients with Crohn's disease and the antibody was also present in all four of 
the patients he tested -who had primary sclerosing cholangitis (Oudkerk Pool 
1993). He fOlll1d no correlation between disease activity and the presence of 
ANCA. The specific .antigen testing proved that the antibodies were neither 
MPO, HLE nor proteinase 3 specific. 
More recently at the 5th international workshop on ANCA in Cambridge, 
September 1993, a number of groups presented their data on ANCA in bowel 
diseases and their findings in ulcerative colitis are summarised in Table 1. 
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Table 1. 
ANCA IN ULCERATIVE COLITIS. SUMMARY OF FINDINGS AT THE 
FIFTH INTERNATIONAL ANCA WORKSHOP 
GROUP NO POS % IIFPATTERN SPECIFICITY 
Patel 101 71 70 P 26%Lf 
Birmingham 
Hauschild 33 17 51 9/17 P 55%HLE 
Lubeck 8/17 X 22%Lz 
Oudkerk Pool 51 37 73 P 
* Amsterdam 
Mann S Asian 10/14 P 0% CG 
Bristol 1 Leicester 18 14 78 3/14 C 
1114 X 
Eur. 
35 30 86 29/35 P 24% CG 
1135 C 
* Combined European study, Amsterdam results. 
Lf Lactoferrin 
CG Cathepsin G 
HLE Human Leucocyte Elastase 
Lz Lysozyme 
It is evident :from this new data that no single ANCA specificity is associated 
with ulcerative colitis. Hauschild's group found that the percentage of ANCA 
positive patients was similar in patients with low (52%), moderate (50%) and 
severe (50%) disease activity. Mann and co workers concluded :from their 
study that there was a significantly higher rate of P-ANCA positivity with 
Cathepsin G specificity in European compared to South Asian patients. They 
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also report that in a recent study it has been suggested that there is a clinical 
difference between these two groups of patients and that these differences 
warrant further investigation (patel 1993, Hauschild 1993, Oudkerk Pool 1993, 
Mann 1993). 
2.2.2 STUDY POPULATION 
Fifty eight patients were recruited from the Gastrointestinal unit at King 
Edward VIII hospital and from local private physicians. Forty four patients 
had ulcerative colitis alone, three patients had ulcerative colitis together with 
sclerosing cholangitis, one patient had sclerosing cholangitis alone, four 
patients had Crohn's disease, five had irritable bowel syndrome and one patient 
had colonic schistosomiasis. The diagnosis of inflammatory bowel disease 
was made on clinical, endoscopic, radiographic and histological grounds. None 
of the patients with inflammatory bowel disease had severe colitis, and all were 
being treated as outpatients. Three of the patients with ulcerative colitis had 
undergone colectomy. The demographic details of the forty four patients with 
ulcerative colitis can be seen in Table 2. 
Table 2 
DEMOGRAPHIC DETAILS OF FORTY FOUR PATIENTS WITH 
ULCERATIVE COLITIS 
DISTRUBITION MEAN AGE RANGE NUMBER 
AGE 
Black female 48 38-60 3 
White female 40 20-60 11 
White male 39 18-61 8 
Indian female 41 19-71 15 
Indian male 33 21-58 6 
Col. female 37 I 
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2.2.3 METHODS 
Patients' serum samples were divided into four tubes and stored at -20oC until 
assayed. Samples were thawed once for testing, re-freezing and thawing of 
sera was avoided. An indirect immunofluorescent assay was done using the 
chamber 16 slide method ( Chapter 1.3.4). All samples were tested in 
duplicate. Samples found positive on the standard normal neutrophil substrate 
were tested on the MPO deficient substrate and they were also tested for 
antinuclear antibody by indirect immunofluorescence. Two screening 
substrates were used: (i) composite block of mouse kidney, liver and stomach 
tissue and (ii) HEp-2 cell line. 
2.2.4 RESULTS 
ANCA was not found in the five patients with irritable bowel syndrome or in 
the patient with schistosomiasis. Two of the four patients with Crohn's disease 
had atypical X-ANCA while two of the three patients who had ulcerative 
colitis with sclerosing cholangitis were found to have P-ANCA and C-ANCA 
respectively. The smglepatient with sclerosing cholangitis alone had P-ANCA. 
The antibodies found in the two patients with Crohn's disease were very 
similar, both exhibiting cell membrane disruption and granule "spill" (Plate 9). 
This same staining peculiarity was observed on the myeloperoxidase deficient 
substrate. One of these patients had a positive antinuclear antibody of 
homogenous pattern with a titre of 1 :200 while the other showed a cytoplasmic 
lysosomal pattern on the composite block mouse tissue section. 
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Plate 9 
ANCA in Crohn's disease ~ neutrophil granule "spill". (Mag. x 300) 
Of the forty four patients with ulcerative colitis twenty five were found to have 
antineutrophil cytoplasmic autoantibodies (57%). Twelve (48%) of these were 
of P-ANCA specificity, ten (40%) showed an atypical staining pattern, X-
ANCA and the remaining three (12%) had the classical granular cytoplasmic 
staining pattern. Of the three patients who had a colectomy one was C-ANCA 
positive. Details of the ANCA distribution in this group of patients can be seen 
in Tab!e 3. All 22 P and X-ANCA positive samples were tested on the 
myeloperoxidase deficient substrate and showed positive fluorescent staining, 
i.e. they were not myeloperoxidase specific. Other autoantibodies were 
identified in this group of patients, one black female with P-ANCA had an 
. antinuclear antibody (homogeneous pattern) at a titre of 1 :200 and tested 
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for antibodies to ds-DNA and extractable nuclear antigens. One white female, 
also P-ANCA positive was found to have cytoplasmic lysosomal antibodies on 
the composite block, similar to those seen in the patient with Crohn's disease. 
Two patients had smooth muscle antibodies and a third patient had antibodies 










* Post colectomy 
ANCA IN FORTY FOUR PATIENTS 
WITH ULCERATIVE COLITIS. 
X-ANCA C-ANCA Total Number 
Positive 
2 3 
2 6 11 
1* 3 8 
6 1 10 15 
1 1 3 8 
1 1 1 











The spectrum of inflammatory bowel disease has been associated for many 
years with autoimmune phenomena. Autoantibodies reactive with colonic 
epithelial cells and lymphocytes were reported in 1959 and 1975 respectively 
(Broberger 1959, Korsmeyer 1975). In an editorial in 1991 "Vasculitis and 
the gut: unwitting partners or strange bedfellows", Prof J T Lie of the Mayo 
Clinic reviewed the involvment of the gut in various vasculitic diseases such as 
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Takayasu's arteritis, Churg Strauss syndrome and Wegener's granulomatosis. 
He concluded 11 The association of vasculitis and inflammatory bowel disease 
cannot be dismissed as an epiphenomenon and it merits our continual 
attention" (Lie 1991). The recent discovery of ANCA in patients with 
inflammatory bowel disease supports the suggestions that Prof Lie made. 
The presence of ANCA has been demonstrated in a group of local Durban 
patients with ulcerative colitis. Fifty seven percent of the patients were 
ANCA positive correlating well with other reports (Saxon 1990, Duerr 1991, 
Halbwachs-Mecarelli 1992). The antibody specificity of the twenty five 
patients is unclear. All the P-ANCA positive patients were also positive on the 
myeloperoxidase deficient substrate therefore excluding MPO specificity as 
has been reported by others. As yet specific antibody tests for other antigens 
such as Lf~ HLE and eG are locally unavailable. None of the ANCA positive 
patients had severe colitis, so the antibody presence was probably unrelated to 
disease activity as documented in three separate studies (Saxon 1990~ Duerr 
1991, Hauschild 1993). Unlike the recently reported study of Mann in 1993, 
in this study population the frequency of P-ANCA does not differ between 
White and Indian patients. However 7/13 (54%) Indian patients have X-
ANCA whereas only 2/9 (220/0) White patients have the atypical X-ANCA. 
Although these numbers are too small for statistical evaluation it is of interest 
that the overall ANCA prevalence varies both between the race groups and the 
sexes. Fifty five per cent of White and 67% of Indian females have ANCA 
compared with 36% White and 38% Indian males. In this study the number of 
patients with Crohn's disease and sclerosing cholangitis was so small that it is 
difficult to comment upon, or to evaluate the results. 
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The pathogenetic importance of ANCA in inflammatory bowel disease is not 
yet known. Some feel that it is unlikely that it is involved in the pathogenesis 
of chronic inflammatory bowel disease, (Gross 1993) while others postulate 
that ANCA may be a manifestation of altered immune regulation in ulcerative 
colitis (Duerr 1991). There is consensus however that ANCA may be a useful 
marker and a helpful test to distinguish between ulcerative colitis and Crohn1s 
disease. 
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2.3 SYMPTOMATIC HIV DISEASE 
2.3.l INTRODUCTION 
Since 1985 autoimmune phenomena have been reported in patients with IllV 
infection. Among the autoantibodies documented in mv infected patients are 
antinuclear factor, rheumatoid factor and anticardiolipin antibodies. In 1990 
ANCA was first described in HIV infection by Koderisch and co-workers. 
U sing the indirect immunofluorescent assay they reported a faint homogeneous 
cytoplasmic staining in thirty one sera from twenty four patients and they 
interpreted this as being non-specific Fc-receptor binding of IgG. Fifteen of 
their patients were hypergammaglobulinaemic and all fifteen showed this 
staining pattern. Definite C-ANCA staining however was found in four serum 
samples from three patients. These authors found no correlation between the 
stage of the disease and the presence of ANCA and cautioned clinicians to be 
aware of "false positive" reactions in IllV infections. In contrast however 
Klaasen and co-workers in 1992 reported the presence of ANCA (IIF testing 
method), in eleven of thirty five patients with symptomatic IllV infection. In 
their study they found that this antibody was not related to the degree of 
hypergammaglobulmaemia nor to any specific patient symptomatology. They 
reported both C and P-ANCA staining patterns, and of great interest was the 
negative reaction with these serum samples when they were tested for PR3, 
MPO and elastase specificity by sandwich ELISA's, immunoprecipitation and 
immuno-blotting. This suggested a possible new specificity for the target 
antigen in HIV associated ANCA. Davenport in 1992 published four case 
reports of "false positive" ANCA in patients with Hodgkins, Tuberculosis, 
haemorrhagic cerebral infarct and IllV disease. Comely in 1993 reported p_ 
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ANCA positivity in 65/1 03 (63.1 0/0) IllV infected patients. Of these 65 patients 
57 had CD4 counts of <200J,.tl and 8 had CD4 counts >2001}l1. He reported no 
association with hypergammaglobulinaemia or the presence of other 
autoantibodies. Immuno-blotting of these P-ANCA's was associated with at 
least four different target proteins of 45kDa, 55kDa, 60kDa and 75kDa 
respectively. 
IllV incidence in the Durban area has increased rapidly over the last five years 
to an incidence of about 100/0 in the Black population (personal communication 
Prof J Moodley ante natal clinic survey). IllV related disease is assuming 
progressively increasing prominence in the medical wards at King Edward VIII 
hospital and Wentworth hospita1. 
ANCA is used routinely for the diagnosis of systemic vasculitis at this hospital. 
The positive predictive value of the test will undoubtedly be influenced by the 
rising mv prevalence, and it was therefore decided to test a cohort of local 
patients with symptomatic mv disease for the presence of autoimmune 
phenomena. 
2.3.2 STUDY POPULATION 
Forty five consecutive patients were recruited from the mv out patient clinic 
at King Edward VIII hospital and six "in" patients at Wentworth hospital. The 
patients from the clinic all had symptomatic disease varying from generalised 
lymphadenopathy to Aids related complex (ARC) and AIDS. None of these 
patients was being treated with AZT, but some were receiving treatment for 
related conditions such as tuberculosis and candidiasis. 
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The patients from Wentworth Hospital were from the neurology wards and had 
been admitted for investigation of various neurological symptoms, including 
paraperesis and cerebro vascular accidents. 
The 51 patients included 22 Black males, 27 Black females and 2 Indian 
males. The demographic details of the Black patients can be seen in Table 4. 
Table 4 
DEMOGRAPHIC DETAILS OF FORTY NINE BLACK mv 
POSITIVE PATIENTS 
MALE FEMALE 
NUMBER 22 27 
MEAN AGE 36 30 
AGE RANGE 20-60 17-52 
2.3.3 METHODS 
Senun samples were divided and frozen at -20oC until tested. Samples were 
thawed once for testing, re-freezing and thawing of sera was avoided. ANCA 
tests were performed in duplicate using the indirect immunofluorescent 
technique in the 16 well chamber slide (Chapter 1.3.4). 
CD4, helper cell counts were enumerated on a Coulter flow cell cytometer, 
EPICS PROFILE II using cytostat Coulter clone T4-RDYT8-FITC 2222E223 
as the detecting antibody. These counts are expressed as the number of cells 
per microlitre. 
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Indirect immunofluorescent screening for antinuclear factor was done on a 
composite block of mouse tissue: liver~ kidney and stomach. Positive sera on 
this substrate were retested on a HEp-2 cell line for antinuclear factor 
confirmation~ Crithidia luciliae for antibodies to ds-DNA and ELISA assays 
for specific antibodies to four extractable nuclear antigens, RNP, Sm~ SSa and 
SSb. 
IgG antiphospholipid antibodies were sought using an "in house" ELISA assay 
with bovine heart cardiolipin extract as the substrate. An index of positivity is 
calculated by dividing the mean of the optical density of the patient's sample 
by 1 ~5 x the mean optical density of the standard negative serum control. An 
index of 1,1-2~5 is considered a low range positive, 2~6-3~5 a medium range 
positive and >3,6 a high range positive. 
2.3.4 RESULTS 
ANCA was found in in twenty one (41%) of the fifty one patients. Fifteen had 
C-ANCA~ three P-ANCA and three an atypical X-ANCA staining pattern. 
Table 5 shows the helper cell counts and the autoantibody findings in the 
twenty one ANCA positive patients. Four of twenty one patients (190/0) had 
ANA that was not specific for ds-DNA or the extractable nuclear antigens 
SSa, SSb Smand RNP. Thirteen of twenty one (62%) had antibodies to 




AUTOANTIBODY AND CD4 COUNTS IN 21 PATIENTS WITH ANCA. 
Pat. no. ANCA CD4 Jpl 
390 C NID 
400 C NID 
5 C 196 
10 C 756 
12 p 73 
13 X 308 
34 C 584 
35 C 260 
36 C 188 
38 C 627 
42 X 412 
43 C 206 
44 C 155 
45 P 354 
46 C 399 
47 P 594 
49 C 626 
53 C 205 
54 C 725 
55 X 120 
56 C NID 
SMAB Smooth muscle antibody 
PCAB Parietal cell antibody 
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Table 6 illustrates the comparison between the autoantibody results and the 
CD4 counts of the ANCA positive and the ANCA negative patients. 
Table 6 
COMPARISON OF HELPER CELL COUNTS AND AUTOANTIBODY 
FINDINGS IN ANCA POSITIVE AND ANCA NEGATIVE mv 
INFECTED PATIENTS. 
ANCA Positive ANCA Negative 
Number 21 30 
CD4 <200 5/19 1260/<1 6/26 1230/<1 
CD4201-400 7/19 (370/~ 8/26 1540/~ 
CD4401-800 7/19 (37%) 10/26 (38,4%) 
CD4 >800 0/19 2/26 17,60/<1 
ANF 4/21 1190/0) 3/30 110%) 
SMAB 13/21 (62%) 11/30 1370/<1 





Helper cell count expressed as number per microlitre 
Antinuclear factor 
Smooth muscle antibody 
Anticardiolipin antibody 
Of the twenty one ANCA positive and thirty ANCA negative patients~ CD4 
counts were available on ninteen and twenty six respectively. There was no 
difference between the CD4 counts in the two groups. Antinuclear antibodies 
63 
were detected in 190/0 of the ANCA positive patients and in 100/0 of the 
ANCA negative group. A high proportion~ 760/0 and 70% of these patients 
were found to have anticardiolipin antibodies. This is in agreement with the 
findings of other workers in this field (Maclean 1990). Smooth muscle 
antibodies were found more frequently~ (620/0) in ANCA positive patients than 
in the ANCA negative patients (37%). 
2.3.5 DISCUSSION 
Concurring with the reports of others (Koderisch 1990~ Klaasen 1992~ Comely 
1993) a high prevalence of ANCA (41%) was found in the IllV infected 
patients with symptomatic disease at King Edward VIII and Wentworth 
hospitals Other than a higher prevalence of smooth muscle antibodies in the 
ANCA positive patients compared to the ANCA negative patients, there were 
no differences between the two groups of patients relating to the helper cell 
counts, antinuclear antibodies and anticardiolpin antibodies. Smooth muscle 
antibodies once thought to be specific for chronic active hepatitis are found in 
about 80% of patients with viral infections and non specific liver damage so 
the non specific nature of the test may explain the high prevalence of this 
antibody in this group of patients ( Chapel R and Raeney M. Essentials of 
Clinical Immunology, 3rdedition 1993). 
ANCA in IllV infected patients does not appear to be associated with any 
clinical symptoms of vasculitis. IllV associated ANCA is probably an 
epiphenomenon related to the breakdown and degranulation of neutrophils 
concomitant with a viral infection~ or the response to a retroviral antigen, or the 
result of immune dysregulation in IllV infection 
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All three patterns of ANCA were found in our patients, the majority, 71 % 
being C-ANCA but the specificities are still ill defined. Clinical manifestations 
of HIV disease and Wegener's granulomatosis may have features in common, 
therefore the finding of C-ANCA in our local patients should be followed by 
an HIV test when the clinical or histological investigations are inconclusive. 
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2.4 INVASIVE AMOEBIASIS 
2.4.1 INTRODUCTION 
Invasion of the body by Entamoebae histolytica commonly manifests with 
ulcerative colitis or amoebic liver abscess (ALA). Interaction between the 
protozoa and polymorphonuclear leucocytes is thought to contribute to the 
pathogenesis of these lesions. It has been shown that contact between virulent 
strains of E. histolytica and neutrophils in vitro is followed by spontaneous 
degranulation and subsequent lysis of neutrophils (Guerrant 1981). The 
liberation of proteolytic enzymes during this process participates in producing 
the hepatic necrosis -characteristic of amoebic liver abscess. 
Features of the pathology of amoebiasis include disruption of neutrophils, 
damage to blood vessels and areas of ischaemic necrosis, particularly in the 
colon (Luvuno 1985). It was therefore postulated that in the setting of 
invasive amoebiasis, components of the damaged neutrophils may in addition 
generate an immune response and that this response could be implicated in the 
vascular pathology of this condition. Accordingly a study of serum samples 
from patients with invasive amoebiasis was initiated. 
2.4.2 STUDY POPULATION 
Eighty two encoded samples from 77 Black adult patients with clinically 
proven ALA were tested. Included was a sequence of sera from one patient at 
the time of diagnosis and at 1, 3 and 8 months of convalescence. Two serial 
samples from each of two additional patients were also examined. Because 
other investigations were used in this amoebiasis study, controls included 
reference C and P-ANCA positive sera from patients with histologically 
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confirmed vasculitis and sera from volunteer adult blood donors. These were 
, 
included as appropriate with each of the methods. 
2.4.3 METHODS 
The serum samples from these patients had been lyophilized and stored at 
-200C. 
Prior to testing they were reconstituted with 200Jll of distilled water. ANCA 
was sought using the indirect immunofluorescent technique on the 16 well 
chamber slides (Chapter 1.3.4). Because of the large numbers~ these samples 
were not tested in duplicate. The tests were read in a blinded fashion by a 
minimum of two observers and the degree of fluorescence graded from 
negative to ++++. Where there was a discrepancy between the observers (n = 
4) the test was repeated in duplicate. 
Tests to demonstrate cross-reacting antibody. 
Indirect immunofluorescence (IIF) on E. histolytica substrate. 
Whole amoebae were washed once in Ringer's solution and adjusted to a count 
of 0,25 x 106/00. 200 J,ll of this suspension was pipetted into the wells of the 
16-chamber slides and allowed to settle for one hour at 370 C in an atmosphere 
of 5% C02 in air. The supernatant was gently syringed off~ the wells dried at 
room temperature for two hours and then the amoebae were fixed for 5 mins 
in cold absolute alcohol. A standard IIF was performed with serum from eight 
patients with amoebiasis~ four with vasculitis associated ANCA (3 C-ANCA~ 1 
P-ANCA) and one normal control. 
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Amoebic gel diffusion test (AGDT) 
The amoebic gel diffusion test was performed as previously described (Jackson 
1983). If no precipitins developed within 40 hours the test was read as 
negative. When precipitins developed within 20 hours the AGDT was 
regarded as strongly positive. The test was done on serum from 87 patients 
with amoebic liver abscess, 6 patients with vasculitis associated ANCA, (5 C-
ANCA and 1 P-ANCA) and 107 normal controls. 
Absorption studies. 
Pure neutrophil suspensions were prepared as detailed (Chapter 1.3.3). Whole 
amoebae were washed once for five minutes at 350 x g in Ringers solution. 
The neutrophils were resuspended in Hank's balanced salt solution and 
adjusted to a cell count of 7,5 x 106/ml. The amoebae were suspended in 
Ringers solution and adjusted to a count of 5~ 4 x 106 Iml, 110JlI of a proteinase 
inhibitor, iodoacetamide was added to one millilitre of each cell suspension to 
achieve an end concentration of 10mM. The neutrophils were sonicated for 
two minutes at 100 watts and the amoebae for four minutes at 100 watts. 
These sonicates were then centrifuged for thirty minutes at 1900 x g. The 
supernatants were removed and the cell debris resuspended in 500pl of PBS. 
These two preparations of the neutrophils and the amoebae were termed 
"sediment and supernatant" . The amoebic antigen used in the amoebic gel 
diffusion test was also used as an absorbent. The seven absorbents are listed 
below. 
1. Phosphate buffered saline. PBS 
2. Whole neutrophils 2 x 106/ml. 
3. Neutrophil sediment. 
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4. Neutrophil supernatant. 
5. Amoebic sediment. 
6. Amoebic supernatant. 
7. Amoebic antigen as used in the AGDT. 
These seven absorbents were each incubated with an equal volume of six 
ANCA amoebic sera, 4 vasculitis associated ANCA (3 C-ANCA and 1 P-
ANCA) and one normal control. The incubation time was for one hour at RT, 
with gentle shaking every ten minutes. The preparations were then centrifuged 
for 10 mills at 1900 x g and the supernatents removed for testing. These 
serum supernatents were then diluted 1 in 5 with PBS to achieve the end 
dilution of 1 in 10 used for the ANCA screening technique. 
Ouchterlony gel diffusion tests. 
The gel diffusion technique described by Ouchterlony (1962) was used. 
100 J.11 of the two antigens, neutrophil sediment and neutrophil supematent were 
placed in the central well of each of two agarose Ouchterlony plates. 45 J.11 of 
positive sera, (3 C-ANCA, 1 P-ANCA, 3 Amoebic-ANCA) and a normal 
serum control were placed in the eight small surrounding wells. The plates 
were incubated in a moist chamber for 48 hours and then examined for 
precipitation lines using a magnifYing glass against a dark background. 
Anti-Proteinase 3 (PR3) ELISA 
Specific anti-proteinase 3 activity was measured using an ELISA test kit 
supplied by Immunobiological Laboratories, Hamburg, according to the 
manufacturer's instructions. A cut off value of lOU/ml was used to separate 
seropositive from seronegative results. Sera of 28 ANeA positive amoebic 
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patients, six vasculitis-associated ANCA patients (3C and 3 P-ANCA) and 10 
volunteer blood donors were tested. 
2.4.4 RESULTS 
Seventy six (98,7%) sera from patients with invasive amoebiasis produced 
unequivocal fluorescence of the neutrophil cytoplasm indicating the presence 
of ANCA. The pattern of staining resembled C-ANCA but was considered to 
be more homogeneous than granular, and lacked any perinuclear emphasis 
(plate13). In the case for whom serial observations were available the ANCA 
became less intense at one month and negative at three months after successful 
treatment (Table 7). One confirmed ALA patient with a negative AGDT and 
one AGDT positive ALA patient were ANCA negative. In the patients for 




Amoebiasis-associated C-ANCA (Mag x 300) 
Table 7 
SERIAL OBSERVATIONS IN PATIENT S27 
DATE MONTHS ANCA AGDT 
18/03/91 0 3CHOM POS 20HR 
12/04/91 1 2CHOM POS 20HR 
20/06/91 3 NEG POS 20HR 
28111/91 8 NEG POS 40HR 
3/2 Grading of fluorescence, negative to 4 (++++) 
C cytoplasmic fluorescence 
HOM homogeneous staining. 
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In the IIF E. histolytica assay all the samples from patients with amoebiasis 
gave definite fluorescence of the amoebae (plate 14). Serum from the 
patients with vasculitis-associated C and P-ANCA and normal controls gave 
negative results. 
Plate 14 
IIF Amoebae (Mag. x 400) 
Six samples from patients with vasculitis-associated ANCA gave negative 
AGDT results with no precipitins observed after 40 hours. Of the 107 control 
samples tested 105 were negative, one was strongly positive at 20 hours and 
another positive at 40 hours. 
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Attempts to absorb ANCA from amoebic and vasculitis-associated serum with 
any of the preparations used for this purpose were unsuccessful (Table 8). 
Table 8 
ABSORPTION STUDIES 
Absorbent N. serum WegC-ANCA Amoeb C-ANCA 
PBS - + + 
Intact neutrophil - + + 
Neutrophil sediment - + + 
Neutrophil supematent - + + 
Amoebic sediment - + + 
Amoebic supernatent - + + 
Amoebic antigen (AGDT) - + + 
NOTE. A possible explanation for the failure to absorb neutrophil antibody 
activity from both vasculitis-associated C-ANCA and amoebiasis-associated 
C-ANCA is that there was antibody excess in the mixtures. Recent reports 
have suggested that absorption of this group of antibodies using neutrophil 
derived antigens is difficult, and recommend that serum should be diluted at 
least 1 in 50 to ensure antigen excess. 
Two of the four Wegener's sera (3 C-ANCA and 1 P-ANCA ) formed lines of 
precipitation in the Ouchterlony gelditIusion test with the neutrophil sonicate 
sediment. No reaction occurred with any of the amoebic sera. There was no 




As can be seen in Fig 13, 75% (21128) ANCA positive sera from patients with 
amoebiasis have specific anti-PR3 activity. All 10 controls and the 3 P-ANCA 
sera had values of <10U/ml, and the 4 C-ANCA patients levels of >80U/ml. 
Plate 15 shows one of the PR3 ELISA test plates. 
Fig 13 
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The twO' DbservatiDns that clearly emerge frDm this study are that 98,70/0 of 
patients tested with invasive amDebiasis have ANCA, with a pattern Df staining 
that suggests PR3 specificity and that the anti-PR3 assay CDnfinns at least a 
degree of PR3 specificity in 750/0 Df these. It was nDted that the staining 
pattern is hDmDgeneDus rather than granular, that there is nO' central emphasis 
and that the reactiDn in bDth IIF and ELISA is less intense suggesting that 
besides the recDgnitiDn Df a PR3 epitDpe Dther specificities may be implicated. 
The first pDssible explanatiDn fDr the presence Df this antibody in amDebiasis is 
that the disruptive effectDf E. histolytica Dn neutrDphils may expDse and/Dr 
alter prDteins, rendering them antigenic and resulting in the prDductiDn Df an 
antibDdy with specificity fDr anepitDpe Df prDteinase 3. The secDnd possibility 
is that the antibDdy is prDduced in respDnse to' an amoebic antigen and that it 
crDSS reacts with neutrDphil cytDplasmic cDmpDnents such as prDteinase 3. 
Attempts to' demDnstrate crDSS reactivity were incDnclusive and more detailed 
immunDchemical studies are required tDexplDre this pDssibility. 
It is postulated that the binding Df ANCA to' proteinases Dn neutrDphil 
membranes activates the neutrDphil and this may result in degranulatiDn with 
resulting tissue damage (GrDss 1993). The demDnstratiDn Df ANCA in 
virtually all cases Df invasiveamDebiasis raises the interesting pDssibility that 
such neutrDphil activatiDn may cDntribute to' hepatic necrDsis and cDIDniC 
vasculitis Dbserved in this cDnditiDn. It is alsO' thDught that ANCA binding to' 
proteinase ligands on endDthelial cells may cDntribute to' the vasculitis seen in 
Wegener's granulDmatDsis ( Savage 1993). A similar direct effect may Dperate 
in invasive amDebiasis. Effective eradicatiDn Df E. histolytica trDphDzDites 
with metronidazDle and inactivatiDn Df prDteinases byendDgenous inhibitDrs, 
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would effectively stop this sequence of events resulting in rapid conversion to 
seronegativity observed in the one patient from whom serial samples were 
obtained. 
Of practical clinical importance is the fact that amoebiasis is associated with a 
high level of C-ANCA positivity. This finding will need to be considered 
when ANCA test results are used in clinical decision making in an area where 
invasive amoebiasis is endemic. 
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2.6 CLINICAL STUDIES 
Serial observations are available on fourteen patients with ANCA associated 
disease and their brief case histories serve to illustrate the clinical applications 
of the ANCA test. 
1. A 36 year old Indian man had recurrent otitis media, tonsillitis and nasal 
ulceration for 3 years. Serial biopsies had not yielded a diagnosis. He then 
became acutely ill in 1987 with fever, arthralgia, right middle lobe 
consolidation and progressive renal failure. 
The ANCA test revealed strong C-ANCA. A similar result was obtained with 
a serum sample that had been taken one year earlier and stored at -20oC. 
Treatment was started with prednisolone and cyclophosphamide and temporary 
haemodialysis was required. 
Response was good and remission has persisted for 6 years. 
ANCA was not detected within a few weeks of starting treatment and has 
remained negative (Pudifin 1989). 
This was the first ANCA test in our laboratory. It was diagnostic, and has 
been a valuable adjunct to monitoring remission. 
2. A 55 year old White man presented with polyarthralgia, haemoptysis and 
renal failure. Right upper lobe consolidation was present on X-ray 
examination. Renal biopsy revealed focal necrotising vasculitis with interstitial 
inflammation. 
The ANCA test was positive - cytoplasmic pattern. 
Treatment included prednisone, cyclophosphamide and haemodialysis. 
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The constitutional and pulmonary features resolved rapidly, but haemodialysis 
has been needed for irreversible renal failure. 
The ANCA test has remained positive despite long term immunosuppressive 
therapy. 
This patient showed an exception to the general finding that ANCA parallels 
disease activity. 
3. A 51 year old White man had chronic sinusitis for 5 years, tinnitus and 
unilateral hearing loss for 3 years, associated with malaise, weight loss, 
intermittent fever and arthralgia. There was no impairment of renal function. 
An ENT surgeon referred the patient when dramatic hearing improvement 
occurred during a short course of prednisone. ANCA test was positive -
perinuclear staining pattern. 
The patient was treated with prednisone and cyclophosphamide and has 
remained well for 2 years. Apart from a spell of weak ANCA positivety for 6 
months in the first year, the serial ANCA tests have been negative on 
treatment. 
An incidental finding in this patient in 1988 was mild myelofibrosis on bone 
marrow biopsy. 
This test proved useful in diagnosis and monitoring. 
4. A 64 year old White male presented with 3 weeks of pyrexia with severe 
malaise and arthralgia. An X-ray of the chest was clear. Urine contained 
protein and granular casts. The ANCA test produced a strong P-ANCA 
pattern and was myeloperoxidase specific. 
Treatment with cyclophosphamide and prednisone produced rapid remission 
which has been maintained for 3 years. 
The ANCA test has remained positive throughout this period. 
ANCA may persist despite clinical remission. 
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5. A 31 year old White man presented with maxillary sinusitis and 
conjunctival injection. A mucosal biopsy showed non-specific chronic 
inflammation. The urine was clear. 
The ANCA test was positive - cytoplasmic pattern. 
Standard treatment produced resolution and the ANCA test became, and has 
remained negative. 
The ANCA test aided early diagnosis. 
6. A 36 year old Indian man presented with a 6 week illness characterised by 
arthralgia, nasal granulomas, segmental pulmonary consolidation, a vasculitic 
rash, encephalopathy with a seizure and acute renal failure . 
The ANCA test was positive - cytoplasmic pattern. 
The illness ran a fulminant course and the patient died of a gastrointestinal 
haemorrhage one month later despite therapy with immunosuppression and 
plasma exchange. 
The ANCA positivity was not affected by the treatment. 
7. A 40 year old Indian woman, admitted with an avascular necrosis of the 
femoral head, was found to be in renal failure with small kidneys. 
Unexplained fever and a markedly elevated ESR prompted a request for the 
ANCA test which was positive, perinuclear pattern, myeloperoxidase 
specific. 
The patient was treated with cyclophosphamide and is maintained on chronic 
ambulatory peritoneal dialysis. 
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Under treatment the ANCA test became negative. However, ANCA positivity 
returned with a reduction in the cyclophosphamide dose, and has remained 
positive since discontinuation after 2 years of therapy. There has been no 
recrudescence of vasculitis. 
P-ANCA in renal limited disease. 
8. A 60 year old Indian woman presented with severe mononeuritis multiplex, 
weight loss and arthralgia with an ESR of 14lmmlhour. 
ANCA test was positive - perinuclear pattern. 
Gradual recovery of the neurolgical features occurred on treatment with 
cyclophosphamide and prednisone. 
ANCA bcame negative and has remained so after cessation of continuous 
therapy for 2 years. 
ANCA aided in diagnosis and management. 
9. A 46 year old Indian female who was on treatment with prednisone for a 
multi-system disease, thought to be systemic lupus erythematosis developed 
severe destructive pneumonia leading to a lobectomy in Cape Town. 
Histology revealed Wegener's granulomatosis. Treatment with cyclo-
phosphamide and prednisone was initiated. At this time, on treatment, the 
ANCA test was negative. 
After withdrawal of treatment 4 years later, the test became positive, C-ANCA 
pattern. Maintenance treatment with cyclophosphamide has been resumed and 
the test is again negative. The patient remains well. 
ANCA test was useful in treatment decisions. 
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10. A 60 year old White male with chronic sinusitis presented after a grand 
mal seizure. Investigation revealed sinus disease and a mass involving the 
base of the skull. Histology of tissue obtained by a trans-sphenoidal biopsy 
showed the presence of a necrotising granuloma. ANCA test was positive, C-
ANCA pattern. 
Treatment with cyclophosphamide produced resolution of the granuloma and 
the ANCA test became and remained negative until his death. 
Bone marrow failure, possibly therapy-related (cyclophosphamide and 
phenytoin) complicated the course and resulted in death 18 months later. 
ANCA assisted in the diagnosis. 
11. A 31 year old Indian female died of acute hepatic failure after a 9 month 
multisytem illness for which a clear diagnosis was never established. 
Thirteen years earlier, splenectomy had been done for chronic nnmune 
thrombocytopenia. 
Features of the terminal illness included pulmonary infiltrates, focal segmental 
glomerulonephritis with vasculitis of interlobular arteries, paraparesis and 
arthralgia. 
Several ANCA tests carried out during the late stages of her illness were 
positive with a strange pattern that we described as M-ANCA "mixed C and 
P". This would now be recognised as X-ANCA. 
The first X-ANCA seen in the author's laboratory. 
12. A 27 year old White man presented with arthralgia, epistaxis, 
haemoptysis, dyspnoea and rapidly progressive renal failure. 
ANCA was positive - cytoplasmic pattern. 
Renal biopsy supported the diagnosis of Wegener's granulomatosis. 
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All constitutional features resolved on treatment with cyclophosphamide and 
prednisone and the ANCA test became and has remained negative. 
The patient remains well on maintenance dialysis without immunosuppressive 
therapy. 
Classical association with Wegener's granulomatosis. 
13. A 10 year old Black girl had generalised lymphadenopathy, hepatospleno-
megaly and profound eosinophilia (37xl09/1). ESR was 129 mm!hr and 
hepatitis B antigen was present in the serum. 
Various biopsies show eosinophil infiltration - "hypereosinophilic syndrome ". 
On two occasions, one year apart ANCA was strongly positive, X pattern. 
An enigmatic association. 
14. A 36 year old Black female was treated for tuberculosis suggested by 
cavitating disease of the right upper lobe and bilateral basal bronchiectasis. 
There was no improvement. 
Futher developements included encephalopathy with seizures, cardiomyopathy, 
proteinuria and renal insufficiency. 
Renal biopsy showed neutrophil infiltration of glomeruli but no granuloma or 
vasculitis. 
ANCA test was stongly positive - cytoplasmic pattern. 
Treatment with cyclophosphamide and prednisone resulted in a marked overall 
improvement. 
ANCA was of diagnostic value in this case. 
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This series of 14 cases illustrate the diverse presentation and varied clinical 
course of the ANCA associated diseases. We have observed both C and P-
ANCA associated Wegener's granulomatosis, immediate and permanent 
clearing of antibody with immunosuppressive therapy and persisting antibody 
in patients in complete remission. In all these cases ANCA was a most useful 
adjunct to the sucessful diagnosis and treatment of these patients. 
84 
2.6 CONTROLS 
Many workers have tested control populations in their environs. Falk and co-
workers in 1988 were unable to demonstrate ANCA in the fifty normal 
controls that they tested. In a comprehensive study of the role of 
autoantibodies in the diagnosis of systemic vasculitis, Bleil's group in 1991 
were unable to detect ANCA in 164 normal controls. The largest control 
group recorded in the literature comprised 319 normal volunteers and 714 
patients with diseases other than of renal, autoimmune or infectious origin 
(Nolle 1989).Using the IIF method of screening all 1033 were ANCA negative. 
Durban has a heterogenous population so it was important to test the local, 
normal population for the presence of ANCA. A total of one hundred and 
ninety nine controls were tested, forty by the original buffy coat smear indirect 
immunofluorescent technique (Chapter 1.2.2) and the remaining one hundred 
and fifty nine by the 16 well chamber slide method (Chapter 1.3.4). The 199 
controls comprised 92 Blacks, 49 Whites and 58 Indians. All but 34 Black 
females were blood donors. These women were used as a control population 
in a separate study and they were all in their third trimester of pregnancy. The 
demographic details of these controls can be seen in Table 9. 
Table 9 
DEMOGRAPHIC DET~S OF ONE HUNDRED AND NINETY NINE 
NORMAL CONTROLS. 
Male Mean age Female Mean age 
Black 36 29 56 27 
White 38 45 11 37 
Indian 48 31 10 29 
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All samples were tested singly and read independently by two workers. If there 
was any disagreement or if a positive result was found, the sample was retested 
in duplicate. 
ANCA was not found in any of the Black control population. Three blood 
donors, two White males and one Indian male were found to have weak P-
ANCA with definite nuclear staining (Plate 16). These three samples when 
tested for ANA were found to be positive on the HEp-2 substrate. The 
antibodies were weak and tests of specificity for ds-DNA and ENA's were 
negative. Of interest was the ages of these three donors 54, 56 and 44, as it is 
well documented that the incidence of antinuclear factor in the normal 
population increases with age. 
Plate 16 
~ Nuclear staining in a control. (Mag. x 300) 
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One White female 47 years old had P-ANCA and a negative test for 
antinuclear antibody. In a recent publication Stroncek (1993) showed that 
neutrophil alloantibodies formed in response to pregnancy or blood transfusion 
react with cytoplasmic antigens causing a false-positive ANCA test. It is 
therefore of interest that the ANCA positive control in this series is a female. 
Because of the anonymity of the controls, further details of this woman are 
unavailable. Kallenberg and co-workers in 1992 reported P-ANCA in 12 of 
252 (5%) blood donors they tested, a much higher prevalence than in this 
control series. 
In conclusion one of the 199 controls tested was P-ANCA positive, a 
prevalence of 0,5% in the local population. This low false positivity rate is 
important when interpreting ANCA results in this area. 
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CONCLUSION 
In 1985 van der W oude published the new and exciting observation that the 
majority of patients with Wegener's granulomatosis have antibodies to a 
cytoplasmic component of neutrophils. The target antigen for this antibody 
was found to be Proteinase 3, a serine protease located in the primary granules 
of the neutrophil. Over the next few years several other neutrophil cytoplasmic 
antibodies were identified in various clinical situations but none of these 
antibodies has the high degree of specificity that Proteinase 3, C-ANCA has 
for Wegener's granulomatosis. 
The first ANCA test was done in the author's labarotory in July 1987 and this 
thesis is based on six years of personal experience with the method and its 
interpretation. 
The initial technique was cumbersome and time consuming, with one test 
sample processed on each slide, so an improved indirect immunofluorescent 
assay was developed for the rapid detection of antineutrophil cytoplasmic 
antibody activity. Sixteen serum samples can now be inexpensively processed 
on one slide, enabling negative, positive C and P-ANCA controls and duplicate 
patient testing to be done simultaneously. The easy washing and handling 
procedure of the 16 well chamber slide technique facilitates a testing time of 
two hours. When warranted, an urgent assay is of great value and can be 
provided, as prompt diagnosis and treatment of patients with systemic 
vasculitis is often critical to the successful management and outcome of the 
condition. Histological diagnosis although always desirable is at times, for 
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various reasons unobtainable. The ANCA test has been of life saving use in 
extremely enigmatic clinical situations. 
As in most of the immunofluorescent techniques the performance and 
interpretation of this test requires a dedicated and experienced operator. 
A new and interesting observation has been made of a disease association of 
ANCA in patients with amoebic liver abscess. Invasive amoebiasis is endemic 
to this region and the finding of C-ANCA in 98,7% of these patients, 75% of 
whom had Proteinase 3 specificity is of great interest. Internationally a high 
prevalence of Proteinase 3 specific C-ANCA has been reported only in 
patients with Wegener's granulomatosis. There is growing evidence of the 
pathogenic role ANCA plays in systemic vasculitis, but the implications of this 
finding for both the pathogenesis and the clinical relevance of ANCA in 
invasive amoebiasis are still to be elucidated. 
This study has confirmed the value of the finding of this autoantibody in the 
settings of vasculitis, renal disease and inflammatory bowel disease. It also 
confirms the emerging evidence of "false positive" ANCA's in the major 
disease of immune-dysregulation, HIV infection. The finding of the varied 
ANCA specificities in the local population of Durban compares well with the 
reports in the literature by numerous workers in this field. 
Although the "false positive" rate of ANCA in the normal volunteer blood 
donor population is low (0,50/0), the fact that both HIV infection and invasive 
amoebiasis are endemic in this area must of necessity be kept in the mind of 
clinicians interepreting ANCA tests in this enviroment. 
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